• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Acetylleucine     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceChemical compoundyago:WikicatAminoAcidDerivativesyago:Abstraction100002137yago:Acetamide114711197yago:Amide114724264yago:Calculation105802185yago:Chemical114806838yago:Cognition100023271yago:Compound114818238yago:DerivedFunction106014730yago:HigherCognitiveProcess105770664yago:Material114580897yago:Matter100020827yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:ProblemSolving105796750yago:Process105701363yago:PsychologicalFeature100023100yago:Relation100031921chemical compounddrugyago:Substance100019613yago:Thinking105770926yago:WikicatAcetamidesumbel-rc:DrugProduct New Facet based on Instances of this Class

Acetylleucine is a modified amino acid used in the treatment of vertigo and cerebellar ataxia. Acetylleucine is also being developed as a possible treatment for several neurological disorders by IntraBio Inc. Clinical trials with acetylleucine for the treatment of three orphan, fatal, neurodegenerative disorders are underway: Niemann-Pick disease type C, GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), and ataxia–telangiectasia. In 2020, IntraBio announced the successful multinational clinical trial results of the Niemann-Pick type C clinical trial. IntraBio is also investigating acetylleucine for the treatment of common inherited and acquired neurological diseases including Lewy body dementia, amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine Ace